NSE ScannerHospitals & Diagnostics · Medical/Nursing Services · NSE: AGARWALEYE · data 2026-10-30
Dr. Agarwal's Health Care Ltd.
In plain words
Price: 10.3% below its 52-week high of ₹567.75.
Delivery: 55.8% of traded shares were kept for delivery over the last 10 sessions, against 56.6% over the last 60.
Latest results: a net profit of ₹45 cr for the quarter ended Jun 2026 (+50.5% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,207 cr |
| Net profit (last 12 months) | ₹148 cr |
| Sales growth, 3 years (yearly) | 26.9% |
| Profit growth, 3 years (yearly) | 12.3% |
At a glance
Promoters 32.3% (-0.1 pts in a year), pledged 0.0%, institutions 65.4%.
P/E 109.5, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 6.8%, ROCE 9.1%, operating margin 14.5%: how much profit it earns on the money it uses.
Debt/equity 0.53, Profit growth 12.3% and sales growth 26.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (6.8%).
- Expensive on earnings (P/E 109.5).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
AGARWALEYE Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹614.02 crore, up 26% YoY and up 8.8% QoQ.
Net profit was ₹45.23 crore, up 50.5% YoY and up 13.9% QoQ.
Operating margin was 27.8% (26.2% a year ago).
EPS was ₹1.43, up 50.5% YoY and up 14.4% QoQ.
AGARWALEYE के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹614.02 करोड़; पिछले साल की तुलना में 26% की बढ़त, पिछली तिमाही की तुलना में 8.8% की बढ़त।
शुद्ध मुनाफ़ा: ₹45.23 करोड़; पिछले साल की तुलना में 50.5% की बढ़त, पिछली तिमाही की तुलना में 13.9% की बढ़त।
ऑपरेटिंग मार्जिन: 27.8% (एक साल पहले 26.2%)।
EPS: ₹1.43; पिछले साल की तुलना में 50.5% की बढ़त, पिछली तिमाही की तुलना में 14.4% की बढ़त।
AGARWALEYEના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹614.02 કરોડ; ગયા વર્ષની સરખામણીએ 26% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 8.8% વધારો.
ચોખ્ખો નફો: ₹45.23 કરોડ; ગયા વર્ષની સરખામણીએ 50.5% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 13.9% વધારો.
ઓપરેટિંગ માર્જિન: 27.8% (એક વર્ષ પહેલાં 26.2%).
EPS: ₹1.43; ગયા વર્ષની સરખામણીએ 50.5% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 14.4% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
31/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 55.0% over the last 20 sessions vs 77.2% in the 40 before (0.71x); shares delivered per day 0.11x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 9/15: 0 insider buy days (promoter group among them) and 2 SAST acquisition days in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 74/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results
- 27 Aug 26Insider SAST disclosure: Catalyst Trusteeship Limited acquired 75,38,303 shares +1.9% next session
- 18 Aug 26Insider SAST disclosure: Invesco Mutual Fund under it's foll… +1 acquired 2,39,38,185 shares 0.0% next session
- 4 Aug 26Results Q1 FY27 results: profit +50.5% YoY +7.8% next session
- 21 May 26Results Q4 FY26 results: profit +21.9% YoY +4.3% next session
- 3 Feb 26Results Q3 FY26 results: profit +51.0% YoY +2.3% next session
- 30 Oct 25Results Q2 FY26 results: net profit ₹29.7 cr -1.0% next session
- 12 Aug 25Results Q1 FY26 results: net profit ₹30.1 cr +1.2% next session
- 29 May 25Results Q4 FY25 results: net profit ₹32.6 cr -4.1% next session
- 15 Feb 25Results Q3 FY25 results: net profit ₹22.3 cr -3.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹614 cr | ₹45 cr | +50.5% | 27.8% | 1.43 |
| Mar 2026 | ₹564 cr | ₹40 cr | +21.9% | 28.6% | 1.25 |
| Dec 2025 | ₹530 cr | ₹34 cr | +51.0% | 27.2% | 1.07 |
| Sept 2025 | ₹499 cr | ₹30 cr | — | 27.3% | 0.94 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 32.33% | 32.34% | 32.36% | 32.39% |
| Foreign institutions (FII) | 49.56% | 57.96% | 57.94% | 58.06% |
| Domestic institutions (DII) | 15.87% | 7.72% | 7.83% | 7.78% |
| Mutual funds | 14.18% | 6.02% | 5.87% | 5.77% |
| Retail investors | 1.67% | 1.66% | 1.53% | 1.46% |
| Number of shareholders | 42,055 | 42,492 | 43,538 | 46,554 |
Common questions
What was Dr. Agarwal's Health Care Ltd.'s latest quarterly profit?
Dr. Agarwal's Health Care Ltd. reported a net profit of ₹45 cr for the quarter ended Jun 2026 (+50.5% on the same quarter a year earlier), on revenue of ₹614 cr.
How much do promoters hold in Dr. Agarwal's Health Care Ltd.?
Promoters held 32.33% of Dr. Agarwal's Health Care Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Dr. Agarwal's Health Care Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.53.
What is Dr. Agarwal's Health Care Ltd.'s P/E ratio?
About 109.5, based on the last 12 months' earnings and a price of ₹509.2 (data 2026-10-30).
What is the 52-week high and low of Dr. Agarwal's Health Care Ltd.?
The 52-week high is ₹567.75 and the 52-week low is ₹401.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Dr. Agarwal's Health Care Ltd. | ₹509.2 | ₹15,493 cr | 109.5 | — | 6.8% | 9.1% | 0.53 | -1.4% |
| Dr. Lal PathLabs Limited | ₹1,906.4 | ₹31,997 cr | 58.9 | — | 21.6% | 25.3% | 0.08 | +23.7% |
| Vijaya Diagnostic Centre Ltd. | ₹1,445.7 | ₹14,906 cr | 79.5 | — | 19.7% | 19.6% | 0.44 | +43.3% |
| Metropolis Healthcare Ltd. | ₹545.65 | ₹11,309 cr | 56.2 | — | 13.4% | 16.3% | 0.15 | +12.3% |
| Thyrocare Technologies Ltd | ₹456.3 | ₹7,274 cr | 51 | 13.1 | 28.8% | 34.2% | 0.09 | +1.5% |
| Nephrocare Health Services Limited | ₹614.55 | ₹6,194 cr | — | — | 9% | 14.6% | 0.07 | +25.4% |
Compare AGARWALEYE with LALPATHLAB in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AGARWALEYE in NSE Scanner →